Fulcrum Therapeutics, Inc. (FULC) stock
FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.71−0.06 (-1.59%)
Close on Nov 16, 2026Market cap $283.06MP/E –Yield –
Fulcrum Therapeutics cash
Cash and short-term investments held at the end of each period.
Fulcrum Therapeutics's cash was $48.47M at Jun 30, 2026. For fiscal 2025 it was $197.53M, up 239.3% from the year before. The highest annual figure on record is $197.53M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $197.53M | +239.3% |
| FY2024 | Dec 31, 2024 | $58.21M | +127.7% |
| FY2023 | Dec 31, 2023 | $25.56M | -27.2% |
| FY2022 | Dec 31, 2022 | $35.10M | -0.9% |
| FY2021 | Dec 31, 2021 | $35.41M | -37.9% |
| FY2020 | Dec 31, 2020 | $57.05M | -41.0% |
| FY2019 | Dec 31, 2019 | $96.71M | +32.9% |
| FY2018 | Dec 31, 2018 | $72.80M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $48.47M | +13.8% |
| Q1 FY2026 | Mar 31, 2026 | $50.26M | +19.2% |
| Q4 FY2025 | Dec 31, 2025 | $197.53M | +239.3% |
| Q3 FY2025 | Sep 30, 2025 | $47.08M | -35.2% |
| Q2 FY2025 | Jun 30, 2025 | $42.59M | -50.9% |
| Q1 FY2025 | Mar 31, 2025 | $42.18M | +5.6% |
| Q4 FY2024 | Dec 31, 2024 | $58.21M | +127.7% |
| Q3 FY2024 | Sep 30, 2024 | $72.63M | +141.5% |
| Q2 FY2024 | Jun 30, 2024 | $86.70M | +155.3% |
| Q1 FY2024 | Mar 31, 2024 | $39.95M | +15.0% |
| Q4 FY2023 | Dec 31, 2023 | $25.56M | -27.2% |
| Q3 FY2023 | Sep 30, 2023 | $30.08M | -66.9% |
| Q2 FY2023 | Jun 30, 2023 | $33.97M | -15.4% |
| Q1 FY2023 | Mar 31, 2023 | $34.73M | +4.3% |
| Q4 FY2022 | Dec 31, 2022 | $35.10M | -0.9% |
| Q3 FY2022 | Sep 30, 2022 | $90.94M | +38.9% |
| Q2 FY2022 | Jun 30, 2022 | $40.15M | -29.3% |
| Q1 FY2022 | Mar 31, 2022 | $33.31M | -66.9% |
| Q4 FY2021 | Dec 31, 2021 | $35.41M | -37.9% |
| Q3 FY2021 | Sep 30, 2021 | $65.47M | -23.2% |
| Q2 FY2021 | Jun 30, 2021 | $56.78M | -25.0% |
| Q1 FY2021 | Mar 31, 2021 | $100.75M | +297.0% |
| Q4 FY2020 | Dec 31, 2020 | $57.05M | -41.0% |
| Q3 FY2020 | Sep 30, 2020 | $85.22M | -16.1% |
| Q2 FY2020 | Jun 30, 2020 | $75.72M | +52.6% |
| Q1 FY2020 | Mar 31, 2020 | $25.38M | -59.4% |
| Q4 FY2019 | Dec 31, 2019 | $96.71M | +32.9% |
| Q3 FY2019 | Sep 30, 2019 | $101.60M | +22.8% |
| Q2 FY2019 | Jun 30, 2019 | $49.63M | +522.1% |
| Q1 FY2019 | Mar 31, 2019 | $62.45M | – |
| Q4 FY2018 | Dec 31, 2018 | $72.80M | – |
| Q3 FY2018 | Sep 30, 2018 | $82.76M | – |
| Q2 FY2018 | Jun 30, 2018 | $7.98M | – |
See a number that looks wrong?